Drug Trial Radar · NCT06423898
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
284
Planned (sponsor's estimate)
Start
Oct 9, 2024
Primary completion
Jul 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en SevillaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Spanish Clinical Research Network - SCReN
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the standard treatment, usually administered in hospitalized patients.
Conditions
- Endocarditis, Infective
Interventions
Ampicillin plus ceftriaxone in continuous infusionDrug
Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis
Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changedDrug
Ampicillin plus ceftriaxone as an intermittent infusion for a minimum of 14 days. After, if the patient is discharged from the hospital, the following treatments, until the 42-day treatment period is completed: 1. Intravenous treatment according to the following regimens: Ampicillin plus ceftriaxone as an intermittent infusion, teicoplanin, daptomycin, dalbavancin or linezolid. 2. Oral treatment according to the following regimens: amoxicillin plus moxifloxacin, amoxicillin plus linezolid, amoxicillin plus rifampin, linezolid plus moxifloxacin or linezolid plus rifampin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical failureTime frame: One year after the end of the treatment
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario de Álava
Alava, Spain · Recruiting
Hospital Universitario de Cruces
Barakaldo, Spain · Active not recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Not yet recruiting
Hospital Clínico de Barcelona
Barcelona, Spain · Not yet recruiting
Hospital Universitario de Donostia
Donostia / San Sebastian, Spain · Active not recruiting
Hospital Universitario Virgen de las Nieves
Granada, Spain · Active not recruiting
Hospital San Pedro
Logroño, Spain · Active not recruiting
Hospital Universitario Gregorio Marañón
Madrid, Spain · Active not recruiting
Hospital Clínico San Carlos
Madrid, Spain · Not yet recruiting
Hospital Universitario La Paz
Madrid, Spain · Not yet recruiting
Hospital Universitario Puerta del Hierro
Madrid, Spain · Active not recruiting
Hospital Universitario Regional de Málaga
Málaga, Spain · Active not recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Active not recruiting
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Spain · Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Spain · Recruiting
Hospital Universitario Virgen Macarena
Seville, Spain · Active not recruiting
Hospital Universitario Virgen del Rocío
Seville, Spain · Recruiting
Hospital Universitari MútuaTerrassa
Terrassa, Spain · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.